Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Novartis Pharma AG New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1…
Novartis wins FDA approval for Cosentyx to treat paediatric HS patients
Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients…
Novartis wins FDA approval for Cosentyx to treat paediatric HS patients
Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients…
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Novartis Pharma AG Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism…
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Novartis Pharma AG Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism…